Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus NYSTATIN AND TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus NYSTATIN AND TRIAMCINOLONE ACETONIDE.
KENALOG IN ORABASE vs NYSTATIN AND TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%).
Category C
Category D/X
Corticosteroid
Corticosteroid